1. Home
  2. RYTM vs MGEE Comparison

RYTM vs MGEE Comparison

Compare RYTM & MGEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • MGEE
  • Stock Information
  • Founded
  • RYTM 2008
  • MGEE 1855
  • Country
  • RYTM United States
  • MGEE United States
  • Employees
  • RYTM N/A
  • MGEE N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • MGEE Electric Utilities: Central
  • Sector
  • RYTM Health Care
  • MGEE Energy
  • Exchange
  • RYTM Nasdaq
  • MGEE Nasdaq
  • Market Cap
  • RYTM 4.3B
  • MGEE 3.8B
  • IPO Year
  • RYTM 2017
  • MGEE N/A
  • Fundamental
  • Price
  • RYTM $66.36
  • MGEE $88.96
  • Analyst Decision
  • RYTM Strong Buy
  • MGEE Sell
  • Analyst Count
  • RYTM 12
  • MGEE 1
  • Target Price
  • RYTM $77.50
  • MGEE $74.00
  • AVG Volume (30 Days)
  • RYTM 585.3K
  • MGEE 185.7K
  • Earning Date
  • RYTM 08-05-2025
  • MGEE 08-06-2025
  • Dividend Yield
  • RYTM N/A
  • MGEE 2.04%
  • EPS Growth
  • RYTM N/A
  • MGEE 6.51
  • EPS
  • RYTM N/A
  • MGEE 3.54
  • Revenue
  • RYTM $136,863,000.00
  • MGEE $687,578,000.00
  • Revenue This Year
  • RYTM $37.56
  • MGEE $9.95
  • Revenue Next Year
  • RYTM $74.99
  • MGEE $3.02
  • P/E Ratio
  • RYTM N/A
  • MGEE $25.01
  • Revenue Growth
  • RYTM 48.88
  • MGEE 6.11
  • 52 Week Low
  • RYTM $40.46
  • MGEE $72.27
  • 52 Week High
  • RYTM $69.89
  • MGEE $109.22
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 60.43
  • MGEE 48.35
  • Support Level
  • RYTM $60.80
  • MGEE $87.31
  • Resistance Level
  • RYTM $64.00
  • MGEE $90.66
  • Average True Range (ATR)
  • RYTM 2.05
  • MGEE 1.76
  • MACD
  • RYTM 0.17
  • MGEE 0.08
  • Stochastic Oscillator
  • RYTM 100.00
  • MGEE 39.35

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About MGEE MGE Energy Inc

MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings. MGE's generation mix is 40% coal, 21% renewable energy, 17% natural gas, and third-party purchased power.

Share on Social Networks: